Fiche centre
USF Health
Tampa — United States
Essais liés8clinical trials
VilleTampalocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07110337
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| BMS-986368 | Myopathies | Phase 2 | NCT06782490 | MSS — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | RECRUITING |
| Lasmiditan | Migraine | Phase 3 | NCT04396236 | PIONEER-PEDS1 — A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | TERMINATED |
| Galcanezumab | Migraine | Phase 3 | NCT04616326 | REBUILD-2 — A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine | ACTIVE_NOT_RECRUITING |
| Lasmiditan | Migraine | Phase 3 | NCT04396574 | PIONEER-PEDS2 — A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | TERMINATED |
| Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system) | Épilepsie | À vérifier | NCT07110454 | DETECT LTFU — Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up | RECRUITING |
| Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system) | Épilepsie | Non applicable | NCT07110337 | DETECT — Diagnosing Epilepsy To EffeCT Change | RECRUITING |
| CC-97540 | Lupus | Phase 2 | NCT07015983 | A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | ACTIVE_NOT_RECRUITING |
| Galcanezumab | Migraine | Phase 3 | NCT03432286 | REBUILD-1 — A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine | ACTIVE_NOT_RECRUITING |